Agios Pharmaceuticals, Inc. (AGIO) — 10-Q Filings

10-Q Filings (6)

• Agios Swings to Loss Amid R&D Surge, Lacking Prior Year's Windfalls — Oct 30, 2025 Risk: medium
  Agios Pharmaceuticals, Inc. reported a net loss of $103.433 million for the three months ended September 30, 2025, a significant decline from the net income of
• Agios Sees PYRUKYND Drive Q2 Revenue Growth — Jul 31, 2025 Risk: medium
  Agios Pharmaceuticals reported product revenue of $7.0 million for the three months ended June 30, 2025, a significant increase from $0.0 million in the same pe
• Agios Pharmaceuticals Files Q1 2025 10-Q — May 1, 2025 Risk: medium
  Agios Pharmaceuticals, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing details its financial position a
• Agios Pharmaceuticals Files Q3 2024 10-Q — Oct 31, 2024 Risk: medium
  Agios Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first
• Agios Pharmaceuticals Files Q2 2024 10-Q — Aug 1, 2024 Risk: medium
  Agios Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first hal
• AGIOS PHARMACEUTICALS, INC. Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: low
  AGIOS PHARMACEUTICALS, INC. (AGIO) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. AGIOS PHARMACEUTICALS, INC. filed a 10-Q report for the period e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX